08:20 AM EDT, 06/30/2025 (MT Newswires) -- INmune Bio ( INMB ) said Monday its phase 2 clinical trial of XPro in patients with early Alzheimer's disease and biomarkers of inflammation did not meet its primary cognitive endpoint.

The primary endpoint was change in cognition over 6 months on the Early Mild Alzheimer's Cognitive Composite (EMACC), a cognitive assessment designed specifically to measure change in early Alzheimer's disease patients, the company said. The 208-patient trial showed no significant difference between XPro and placebo on the EMACC cognitive scale.

However, XPro was well tolerated with no serious safety issues, INMune Bio ( INMB ) said, and the company still intends to file for Breakthrough Therapy Designation from the US Food and Drug Administration.

Shares of INmune Bio ( INMB ) were nearly 61% lower in recent Monday premarket activity.